Navigation Links
Hutchinson Center and TGen scientists discover potential 'break through' in pancreatic cancer
Date:3/20/2012

PHOENIX, Ariz. -- Scientists at Fred Hutchinson Cancer Research Center and the Translational Genomics Research Institute (TGen) have discovered a literal 'break through' in pancreatic cancer.

A unique biological barrier that pancreatic cancer tumors build around themselves have made them especially resistant to chemotherapy treatments, according to the Hutchinson Center/TGen study published today in the highly-regarded journal Cancer Cell.

Pre-clinical experiments show that a combination of drugs could break down the barrier surrounding these tumors, allowing chemotherapy drugs to freely spread and permeate throughout the cancerous tissue, according to the study.

"Discovering how to break through this barrier is a significant finding that could eventually enable therapeutic compounds to be much more effective in combating this deadly cancer and helping patients," said Dr. Daniel Von Hoff, M.D., TGen's Physician-In-Chief and one of the authors of the study, as well as one of the world's leading authorities on pancreatic cancer.

"The barrier surrounding pancreatic ductal adenocarcinoma has prevented therapeutics from reaching and effectively acting on this cancer," said Dr. Von Hoff, who also is head of TGen's Clinical Translational Research Division.

This research is now being tested for the first time in patients in the U.S. and Europe, including those at Seattle Cancer Care Alliance, the Hutchinson Center's patient treatment arm. These tests have the potential to significantly increase the length of survival in patients with pancreatic cancer, which is notoriously fast-spreading and among the most lethal of all cancers, the study says.

Dr. Sunil Hingorani, M.D., Ph.D., the study's senior author and an associate member of the Hutchinson Center's Clinical Research and Public Health Sciences divisions, developed the study's laboratory model. By combining gemcitabine the current standard chemotherapy used to treat patients' pancreatic ductal adenocarcinomas with an enzyme called PEGPH20, scientists showed that the tumor barrier could be broken down and the drug could more easily reach the cancerous tissue.

"This represents the largest survival increase we've seen in any of the studies done in a preclinical model, and it rivals the very best results reported in humans," Dr. Hingorani said. "Being able to deliver the drugs effectively into the tumor resulted in improved survival as well as the realization that pancreas cancer may be more sensitive to conventional chemotherapy than we previously thought."

Unlike most solid tumors, pancreas tumors use a two-pronged defense to keep small molecules, such as those contained in chemotherapy, from entering: a vastly reduced blood supply and the creation of a strong fibro-inflammatory response. The latter includes the production of fibroblasts, immune cells and endothelial cells that become embedded within a dense and complex extracellular matrix throughout the tumor. One major component of this matrix is a substance called hyaluronan, or hyaluronic acid (HA). HA is a glycosaminoglycan, a complex sugar that occurs naturally in the body and is secreted at extremely high levels by pancreatic cancer cells.

Dr. Hingorani, Dr. Von Hoff and their colleagues discovered that the fibro-inflammatory response creates unusually high interstitial fluid pressures that collapse the tumor's blood vessels. This in turn prevents chemotherapy agents from entering the tumors. The researchers found that HA is the main biological cause of the elevated pressures that leads to blood vessel collapse.

Administering the enzyme/gemcitabine combination degrades HA in the tumor barrier and results in rapid reduction of the interstitial fluid pressure. This in turn opens the blood vessels and permits high concentrations of chemotherapy to reach the tumor.


'/>"/>
Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Hutchinson Center receives $10.24 million from NIH for Latina breast cancer research
2. Hutchinson Center and China CDC sign agreement for research and training collaboration
3. Fred Hutchinson Cancer Research Center scientist receives Presidential Early Career Award
4. NCI awards $11.5 million to Fred Hutchinson Cancer Research Center to lead breast cancer consortium
5. Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network
6. Shanghai CDC and Hutchinson Center establish Shanghai Breast Health Resource Center
7. Hutchinson Center receives $8.2M to coordinate obesity and cancer consortium
8. Fred Hutchinson Cancer Research Center to co-lead 1 of 5 NCI-funded proteomics research centers
9. Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa
10. Hutchinson Center scientists break through pancreas cancer treatment barrier
11. Diet-to-Go Welcomes 2 Key Philadelphia Fitness Centers as Partners-in-Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... , ... With expansion and efficiency in mind, Patten Seed Company completed relocation ... plant opened in Marshallville in 2006, and a bagging and shipping facility has been ... of Patten Seed operations to the Middle Georgia location from their previous home in ...
(Date:3/28/2017)... MO (PRWEB) , ... March 28, 2017 , ... ... of job satisfaction in their profession as their value increases in the healthcare ... that provides resources such as job boards, career fairs, and candidate leads to ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... clear braces. People who want straight teeth without the extensive time commitment and ... Clearwater, FL, without acquiring a referral. A custom-designed series of virtually invisible aligners ...
(Date:3/27/2017)... and London UK (PRWEB) , ... March 27, ... ... speed, agility and ability to gain site attention and engagement over the household ... educational webinar will discuss how partnering with the right outsourcing ...
(Date:3/27/2017)... ... 27, 2017 , ... Buzzies parent company, The TouchPoint Solution’s CEO and co-founder, ... and UBS’ Project Entrepreneur. Mayo will present her pitch about the lifestyle wearable devices, ... second annual venture competition ignites bold ideas by providing women access to the tools, ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... March 27, 2017 Summary ... understand Eli Lilly and its partnering interests and activities since ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ... data. The report will be delivered in PDF ...
(Date:3/27/2017)... 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology ... toxicology and efficacy studies. The company is harnessing the ... protein, MAGE A, in an effort to find a ... After 4 weeks of treatment in transgenic mice, ... toxicity in a full toxicology report of various organs. ...
(Date:3/27/2017)... , March 27, 2017 ... 7,000 attendees and more than 600 exhibitors from ... discover opportunities and solutions that will advance the ... April 2017 at the Messe Stuttgart, ... preeminent medical technology platform showcasing the key trends ...
Breaking Medicine Technology: